News
A Canadian-made generic Ozempic is poised to enter the market
With a vision for building something meaningful, our founder brings a blend of big-picture thinking and hands-on experience. They set the tone for everything we do.
Vimy Pharmaceuticals, KITAM Science, and ABCHealth partner to open a quality-assured medicines corridor into Africa
Focused, approachable, and driven by results, our sales manager is all about building strong relationships. They help connect people to the right solutions—with clarity and care.
Harmony Acquisitions Announces Proposed Qualifying Transaction with Vimy Pharmaceuticals
Harmony and Vimy Pharma are pleased to announce that they have entered into a non-binding letter of intent dated August 4, 2026 (the "LOI"), pursuant to which Harmony and Vimy Pharma intend to complete a business combination or other similarly structured transaction which will constitute a reverse take-over of Harmony (the "Transaction").
Canadian-made generic Ozempic could be manufactured in Edmonton
Generic versions of Ozempic can now enter the Canadian market. One company, created by Canadians and based in Toronto, is looking to make the drug on domestic oil.
Generic Ozempic is coming to Canada. This company wants to make it
A Canadian pharmaceutical company, headed by two former executives with the company behind Ozempic, hopes to make a generic version of the weight-loss drug in Edmonton.
Canada will be a launching pad in the global race for generic Ozempic
Dave Suchon, the chief executive officer of Vimy Pharma, said he and co-founder Farris Smith formed the company to create a Canadian-made and Canadian-owned producer of generic semaglutide.
A regulatory manufacturing team with deep Canadian experience: Vimy Pharmaceuticals
Farris Smith, founder & president of Vimy Pharmaceuticals, joins BNN Bloomberg to discuss 2026 outlook on the weight loss drugs space.
Canadian firm enters race to bring generic Ozempic to market
As the race among drug makers heats up to deliver a generic form of the blockbuster drug Ozempic next year, Vimy Pharmaceuticals Inc., a new entrant to the field, is aiming to produce a made-in-Canada version.
The race to making the Canadian version of Ozempic
Vimy Pharma co-founder and CEO, Dave Suchon, discusses the company and the GLP-1 space in Canada with Andrew Bell on BNN’s “The Open” on October 17, 2025
‘The potential is phenomenal’: Drug maker Vimy Pharma plans to produce made-in-Canada, generic version of Ozempic
Canadian company Vimy Pharma aims to produce a generic version of blockbuster drug Ozempic to provide an affordable option for health-conscious consumers in the country.
‘We’re going to be making it here in Canada,” Dave Suchon, co-founder of Vimy Pharma told BNN Bloomberg in a Friday interview. “We’ve done our research and development here in Canada as well.”
Affordable Ozempic could soon be within reach for millions of Canadians
Vimy Pharma’s entry could mark a turning point for Canadian patients and plan sponsors seeking cost-effective solutions for chronic conditions
The race to making the Canadian version of Ozempic
The company’s name pays tribute to the Battle of Vimy Ridge, reflecting a sense of national pride and connection to Canada’s scientific heritage. Suchon and Smith said they were inspired by Frederick Banting and Charles Best, who, along with John Macleod and James Collip, discovered insulin in 1921, a breakthrough that transformed diabetes care worldwide.
More than 100 years later, Vimy Pharma hopes to mark the next chapter in Canada’s long history of leadership in diabetes research.
Vimy Pharma Partners with Wounded Warriors Canada, Pledges Portion of Profits to Support Veterans and First Responders
Vimy Pharma, a proudly Canadian pharmaceutical company dedicated to producing high-quality, affordable medicines, today announced a partnership with Wounded Warriors Canada, a national leader in mental health services for Veterans, First Responders, and their families.
Pharmaris Canada to Lead Sales and Marketing for Vimy Pharma Products Across Canada
Two proudly Canadian pharmaceutical companies announced today a strategic partnership that reinforces their shared commitment to serving Canadian patients. Under the agreement, Pharmaris will assume responsibility for all sales and marketing activities for Vimy Pharma product portfolio across Canada.
This landmark collaboration unites two homegrown Canadian pharmaceutical organizations, both with deep roots in the Canadian healthcare landscape. The partnership exemplifies Canadian innovation and entrepreneurship in action, while strengthening domestic pharmaceutical capabilities and expertise.
Organizational update regarding Dr. Sean Wharton
Vimy Pharma would like to thank Dr. Wharton for his support as Chief Medical Officer and to announce that, effective June 2025, he is no longer in that role.
Vimy Pharma remains committed to its three-part mission to increase access to important medicines for Canadians and contribute to the sustainability of the healthcare system, while supporting Canadian manufacturing. Vimy Pharma would also like to recognize Dr. Wharton for his important work as a global key opinion leader in the field of chronic disease, helping to bring treatment guidelines and options to patients living with chronic disease.